Ушбу иш иқтибос қилган ишлар

361 та иш

Иш: Epigenetic mechanisms and next-gen editing platforms in hematology: From molecular basis to therapeutic frontiers

1. Unveiling the potential of CLL-1: a promising target for AML therapy

   Hamed Soleimani Samarkhazan, Sara Zehtabcheh, Hamideh Rahmani Seraji +4

   Шарҳ мақола20256 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.109473

2. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors

   Enli Liu, David Marín, Pinaki P. Banerjee +24

   Мақола20206 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.312682

3. Aqueous and ethanolic extracts of Moringa oleifera leaves induce selective cytotoxicity in Raji and Jurkat cell lines by activating the P21 pathway independent of P53

   Leila Rajabi, Mostafa Ebrahimdoost, Seyed Amin Mohammadi +3

   Мақола20255 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.109472

4. Modified lentiviral globin gene therapy for pediatric β0/β0 transfusion-dependent β-thalassemia: A single-center, single-arm pilot trial

   Shiqi Li, Sikai Ling, Dawei Wang +17

   Мақола20245 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.312835

5. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells

   Levi J. Rupp, Kathrin Schumann, Kole T. Roybal +4

   Мақола20174 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.020478

6. Platelet-derived extracellular vesicles: emerging players in hemostasis and thrombosis

   Aziz Kubaev, Fadhil Faez Sead, Mohammad Pirouzbakht +6

   Шарҳ мақолаExtracellular vesicles in diseaseJournal of Liposome Research20254 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.109475

7. Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression

   Lei S. Qi, Matthew H. Larson, Luke A. Gilbert +4

   Мақола20133 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.051601

8. Delivering CRISPR: a review of the challenges and approaches

   Christopher A. Lino, Jason C. Harper, James P. Carney +1

   Шарҳ мақола20183 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.051686

9. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

   Stephen J. Schuster, Michael Bishop, Constantine S. Tam +21

   Мақола20183 иқтибос

   ABIABI:AkademIndex/openalex/2026.other.296843

10. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

    Shannon L. Maude, Theodore W. Laetsch, Jochen Buechner +32

    Мақола20183 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.312621

11. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

    Kevin Pan, Hizra Farrukh, Veera Chandra Sekhar Reddy Chittepu +3

    Шарҳ мақола20223 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.312769

12. High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells

    Yanfang Fu, Jennifer A Foden, Cyd Khayter +4

    Мақола20132 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.051539

13. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage

    Nicole M. Gaudelli, Alexis C. Komor, Holly A. Rees +4

    Мақола20172 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.051667

14. The CRISPR tool kit for genome editing and beyond

    Mazhar Adli

    Шарҳ мақола20182 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.051685

15. TRAPT: a multi-stage fused deep learning framework for predicting transcriptional regulators based on large-scale epigenomic data

    Guorui Zhang, Chao Song, Mingxue Yin +6

    Мақола20252 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.065083

16. CRISPR-engineered T cells in patients with refractory cancer

    Edward A. Stadtmauer, Joseph A. Fraietta, Megan M. Davis +38

    Мақола20202 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102870

17. Deletion of the inhibitory co-receptor CTLA-4 enhances and invigorates chimeric antigen receptor T cells

    Sangya Agarwal, M. Ángela Aznar, Andrew J. Rech +17

    Мақола20232 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.102947

18. Epigenetic frontiers: miRNAs, long non-coding RNAs and nanomaterials are pioneering to cancer therapy

    Rajkumar Prabhakaran, Rajkumar Thamarai, Sivabalan Sivasamy +6

    Шарҳ мақола20242 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.112341

19. “Galectin-9: A double-edged sword in Acute Myeloid Leukemia”

    Omolbanin Sargazi-Aval, Ali Ahmadi, Ali Jihad Hemid Al-Athari +5

    Шарҳ мақола20252 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.138194

20. Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapies

    Sara Zehtabcheh, Hamed Soleimani Samarkhazan, Marjan Asadi +3

    Шарҳ мақола20252 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.138195

21. C-type lectin-like molecule-1 as a diagnostic, prognostic, and therapeutic marker in leukemia

    Hamed Soleimani Samarkhazan, Sara Zehtabcheh, Sajjad Peyvasteh +1

    Шарҳ мақола20252 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.138196

22. Nanotechnology in leukemia therapy: revolutionizing targeted drug delivery and immune modulation

    Ashok Kumar Bishoyi, Sina Nouri, Ahmed Hussen +3

    Шарҳ мақола20252 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.138197

23. Non-homologous DNA end joining and alternative pathways to double-strand break repair

    Howard H. Chang, Nicholas R. Pannunzio, Noritaka Adachi +1

    Шарҳ мақола20172 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.194009

24. Epigenetic Therapeutics: A New Weapon in the War Against Cancer

    Nita Ahuja, Anup Sharma, Stephen B. Baylin

    Шарҳ мақола20162 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.204059

25. The Long Noncoding RNA MEG3 and its Target miR-147 Regulate JAK/STAT Pathway in Advanced Chronic Myeloid Leukemia

    Zi-ye Li, Lin Yang, Xiaojun Liu +3

    Мақола20182 иқтибос

    ABIABI:AkademIndex/openalex/2026.other.224072